Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

62.5%

5 terminated/withdrawn out of 8 trials

Success Rate

28.6%

-57.9% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

7(87.5%)

Early Phase 1

1(12.5%)

8Total

Phase 1(7)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06177171Phase 1Recruiting

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

Role: lead

NCT01543763Phase 1Completed

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

Role: lead

NCT05472220Phase 1Withdrawn

Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma

Role: lead

NCT04498520Phase 1Withdrawn

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Role: lead

NCT03318445Phase 1Completed

Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair

Role: lead

NCT02620839Phase 1Terminated

Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies

Role: lead

NCT02358200Phase 1Terminated

Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer

Role: lead

NCT02735798Early Phase 1Withdrawn

64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets

Role: lead

All 8 trials loaded